TIKCRO TECHS ..Kurs rebelliert

ISIN: IL0010848963 ..buran

Datum Erster Hoch Tief Schluss     Stücke Volumen
11.10.13 0,62 0,62 0,60  0,60 $ 8.166 5.060

..und geh weg von mir ..ich das buran brauche kein Trost und erst Recht kein Mitleid von Dir ..ich habe keinen Bock und auch keine Lust mehr ..ich das buran laufe meinen Träumen nicht mehr hinterher ..::hopshopshopshopshopshopshopshopshopshops

Kosmonova buran

Datum Erster Hoch Tief Schluss     Stücke Volumen
  04.11.13      0,60      0,60§0,60 0,60 $ 833 100

GrB

:::::::: 0,64 $ +6,67% +0,04 $ In Euro: 0,4761 € | Nasdaq OTC Other, 14.11.13 ,GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
  25.11.13     0,565     0,565§0,565 0,565 $ 249 141

GrB

::::::::::::: 0,58 $ +11,54% +0,06 $
In Euro: 0,4259 € | Nasdaq OTC Other, 06.01.14 , GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
06.03.14 0,60 0,60 0,60  0,60 $ 120 60
03.03.14 0,53 0,53 0,53  0,53 $ 1.033 468
28.02.14 0,53 0,53 0,53  0,53 $ 9.942 5.265
24.02.14 0,53 0,53 0,53  0,53 $ 306 106
20.02.14 0,52 0,52 0,52  0,52 $ 10.540 5.460
18.02.14 0,561 0,561 0,561  0,561 $ 400 224
12.02.14 0,561 0,561 0,561  0,561 $ 149 56
11.02.14 0,56 0,56 0,56  0,56 $ 599 326
05.02.14 0,56 0,56 0,56  0,56 $ 199 93
04.02.14 0,57 0,57 0,57  0,57 $ 9.984 5.691
29.01.14 0,53 0,61 0,5272  0,61 $ 43.684 23.305
28.01.14 0,53 0,53 0,53  0,53 $ 116 53
22.01.14 0,53 0,53 0,53  0,53 $ 7.090 3.710
21.01.14 0,53 0,53 0,51  0,51 $ 4.037 2.079
17.01.14 0,53 0,53 0,53  0,53 $ 1.166 618
15.01.14 0,53 0,53 0,53  0,53 $ 784 282
06.01.14 0,58 0,58 0,58  0,58 $ 703 408

GrB

http://www.ariva.de/news/...ports-Fourth-Quarter-2013-Results-4980987 GrB

Certain of the statements contained herein may be considered forward-looking statements that involve risks and uncertainties including, but not limited to, risks related to our ability to raise financing and the business of BioCancell, including, but not limited to, the development, testing, regulatory approval and commercialization of its products, its intellectual property rights, its funding, its competition, its exposure to lawsuits and its dependence on key suppliers and personnel. Such risks and uncertainties are set forth in the Company's SEC reports, including the Company's Forms 20-F. Actual results may materially differ. Results of operations in any past period should not be considered indicative of the results to be expected for future periods.  We undertake no duty to update any forward-looking information.http://www.ariva.de/news/...ports-Fourth-Quarter-2013-Results-4980987  

http://www.ariva.de/news/...eports-First-Quarter-2014-Results-5067399 GrB

http://www.ariva.de/news/...ports-Second-Quarter-2014-Results-5117155 GrB

is seeking early stage growth opportunities.

For more information, visit Tikcro website at www.tikcro.com.  

contained herein may be considered forward-looking statements that involve risks and uncertainties including, but not limited to, risks related to our ability to raise financing and the risks related to early stage biotechnology projects, including, but not limited to, the development, testing, regulatory approval and commercialization, intellectual property rights, competition, exposure to lawsuits and dependence on key suppliers and personnel. Such risks and uncertainties are set forth in the Company's SEC reports, including the Company's Forms 20-F. Actual results may materially differ. Results of operations in any past period should not be considered indicative of the results to be expected for future periods.  We undertake no duty to update any forward-looking information. http://www.ariva.de/news/...ports-Second-Quarter-2014-Results-5117155

Datum Erster Hoch Tief Schluss     Stücke Volumen
  20.10.14      0,48      0,48§0,48 0,48 $ 1.133 544

GrB

Der Rückkauf oder die Rückzahlung einer Schuld an den Kreditgeber (Gläubiger) wird als Tilgung bezeichnet. Schuldverschreibungen (festverzinsliche Wertpapiere wie Anleihen, Pfandbriefe oder Obligationen) werden entsprechend den Emissionsbedingungen getilgt. Diese stehen auf jedem Wertpapier. http://www.ariva.de/extras/lexikon.m?begriff=Tilgung

:::::::::::::: 0,52 $ +0,97% +0,005 $
In Euro: 0,4391 € | Nasdaq OTC Other, 09.01.15 ,GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
  10.02.15      0,47    0,5526§0,47 0,5526 $ 7.437 3.917

GrB

::::::::: 0,55 $ ,GrB

http://www.ariva.de/news/list.m GrB

http://www.ariva.de/dow-jones-industrial-average-index/news GrB

gehen mit leichten Gewinnen in die Ostertage

22:40 02.04.15


Die US-Anleger gehen gelassen in die Feiertage. Sie fiebern zwar dem US-Arbeitsmarktbericht entgegen, der am Freitag veröffentlicht wird. Reagieren können sie aber erst am Montag. Nun heißt es abwarten. http://www.ariva.de/news/...eichten-Gewinnen-in-die-Ostertage-5329028

buran

Tikcro Opens Offices and Lab at Kiryat Weizmann Science Park in Israel
14:40 29.02.16

PR Newswire

TEL AVIV, Israel, Feb. 29, 2016

TEL AVIV, Israel, Feb. 29, 2016 /PRNewswire/ -- Tikcro Technologies (OTCQX: TIKRF), a developer of next generation antibodies for immune modulators cancer treatment, announced today the opening of its new offices and lab at the Kiryat Weizmann Science Park in Ness Ziona, Israel.

Since 2014, Tikcro has been developing certain new antibodies in the immune modulator area. Tikcro's new location will support this effort and a continuous research with academic institutes.

"We expect 2016 to be a busy year for the validation, first production and a wide scope of in-vitro trials for our new antibodies," said Aviv Boim, CEO. "With this new facility we will better support our research plan, recruitment of researchers, suppliers and service providers." http://www.ariva.de/news/...t-Weizmann-Science-Park-in-Israel-5665170

http://www.ariva.de/news/...Quarter-and-Year-End-2015-Results-5699861 GrB

http://www.ariva.de/news/...c-t-i-o-n-tikcro-technologies-ltd-5841685 GrB

Meeting
Mittwoch, 23.11.2016 15:10 von PR Newswire  http://www.ariva.de/news/...unces-2016-annual-general-meeting-5958097

TEL AVIV, Israel, Sept. 6, 2017 /PRNewswire/ -- Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced it has successfully humanized its CTLA-4 blocking antibodies. The Company also reported its financial results for the second quarter ended June 30, 2017. http://www.ariva.de/news/...ounces-full-human-ctla-4-blocking-6451332